Advertisement

U.S. Markets closed

S&P Futures
5,888.00
-8.25(-0.14%)
Dow Futures
43,133.00
-44.00(-0.10%)
Nasdaq Futures
20,473.50
-46.00(-0.22%)
Russell 2000 Futures
2,250.50
-5.00(-0.22%)
Crude Oil
70.27
-0.29(-0.41%)
Gold
2,743.70
+4.80(+0.18%)

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

33.67

-0.87

(-2.52%)

At close: 04:00PM EDT

33.67

0.00

(0.00%)

After hours:

04:02PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference
Clinical Trials Arena
Supernus’ depression drug improved symptoms in two hours in Phase IIa study
SPN-820 is being developed to provide fast symptom improvement in patients with depression.